NEW YORK (GenomeWeb News) – CombiMatrix today said it has closed its public offering of 12,000 units of Series D convertible preferred stock and warrants, raising $12 million in gross proceeds.

The units were priced at $1,000 each, and consisted of one share of Series D convertible preferred stock — which can be converted into 485.4369 shares of common stock at a conversion price of $2.06 per share — and one warrant to purchase 485.4369 shares of common stock at an exercise price of $3.12 per share.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Rare gene mutations are guiding the search for drugs to manage chronic pain without opioids, according to CNBC.

The new Francis Crick Institute building can get too noisy for some researchers to concentrate, according to the Guardian.

CBS News reports that there are still many vacancies at the White House Office of Science and Technology Policy, but that it's uncertain whether they will be filled.

In Nucleic Acids Research this week: pipeline to analyze and visualize bacterial genomes, database of global set of human genomes, and more.